

HHC Glossary and Reference Citations

Glossary

AASLD, American Association for the Study of Liver Diseases

ACS, American Cancer Society

AEs, adverse events

AFP, alpha-fetoprotein

ALB, albumin

AST, aspartate transaminase

BID, twice per day

BILI, bilirubin

BP, blood pressure

CCA, cholangiocarcinoma

CT, computerized tomography

CTCAE, Common Terminology Criteria for Adverse Events

Dx, diagnose(d)

Dz, disease

ECOG, Eastern Cooperative Oncology Group

F/U, follow-up

HBsAg, hepatitis B surface antigen

HBV, hepatitis B virus

HCC, hepatocellular carcinoma

HCV, hepatitis C virus

HFS, hand-foot syndrome

HTN, hypertension

Hx, history

ICIs, immune checkpoint inhibitors

mets, metastases

mPFS, median progression-free survival

mRECIST, modified response evaluation criteria in solid tumors

NASH, non-alcoholic steatohepatitis

NCCN, National Comprehensive Cancer Network

NP, nurse practitioner

OS, overall survival

OTC, over the counter

PA, physician assistant

PCR, polymerase chain reaction

PFS, progression-free survival

PT/INR, prothrombin time/International Normalized Ratio

pt(s), patient(s)

QD, once per day

QOL, quality of life

RECIST, response evaluation criteria in solid tumors

R/O, rule out

SOC, standard of care

SHARP, Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol

TKI, tyrosine kinase inhibitor

Tx, treatment/treated

VEGFR, vascular endothelial growth factor receptor

w/, with

wk(s), week(s)

HHC Glossary and Reference Citations

References

Alhasan A, Cerny M, Livie D, et al. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features. *Abdom Radiol* (NY). 2019;44:517–528.

American Cancer Society (ACS). *Global Cancer Facts & Figures, 4th Edition*. Atlanta: American Cancer Society; 2018.

ASCO. FDA grants breakthrough therapy designation to pembrolizumab plus lenvatinib in advanced HCC. ASCO Post. July 23, 2019. <https://www.ascopost.com/News/60276>. Accessed December 11, 2019.

Cheng A-L, Qin S, Ikeda M, et al. IMbrave150: Efficacy and safety results from a phase 3 study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Presented at: European Society for Medical Oncology (ESMO); November 23, 2019; Singapore. Abstract LBA3.

de Santis A, Gallusi G. Diagnostic imaging for hepatocellular carcinoma. *Hepatology Res*. 2019;5:1.

Heimbach JK, Kulik LM, Finn RS. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology*. 2018;67:358–380.

Ikeda M, Kobayashi M, Tahara M, Kaneko S. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. *Expert Opin Drug Safety*. 2018;17:1095–1105.

Inoue T, Tanaka Y. The role of hepatitis B core-related antigen. *Genes* (Basel). 2019;10:357.

Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond. *World J Gastroenterol*. 2019;25:789–807.

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. *Lancet*. 2018;391:1163–1173.

Le MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH. Chronic hepatitis B prevalence among foreign-born and US-born adults in the United States, 1999–2016. *Hepatology*. 2019 Jun 22. [Epub ahead of print]

Lee M, Ryoo B-Y, Hsu C-H, et al. Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Presented at: European Society for Medical Oncology (ESMO); September 27–October 1, 2019; Barcelona, Spain. Abstract LBA39.

Lenvatinib [Lenvima® package insert]. Woodcliff Lake, NJ: Eisai Inc.; 2019.

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359:378–390.

Llovet JP. Hepatocellular carcinoma. *Nat Rev Dis Primers*. 2016;2:16018.

Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2018;68:723–750.

National Cancer Institute. *Common Terminology Criteria for Adverse Events (CTCAE), version 5.0*. November 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed December 11, 2019.

National Comprehensive Cancer Network. *Hepatobiliary Cancers*. Version 3.2019 – August 1, 2019. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed December 11, 2019.

Pembrolizumab [Keytruda® package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2019.

Petrick JL, Campbell PT, Koshiol J, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project. *Br J Cancer*. 2018;118:1005–1012.

Ramucirumab [Cyramza® package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.

Sechidis K, Papangelou K, Metcalfe P, Svensson D, Weatherall J, Brown G. Distinguishing prognostic and predictive biomarkers: an information theoretic approach. *Bioinformatics*. 2018;34:3365–3376.

Schima W, Heiken J. LI-RADS v2017 for liver nodules: how we read and report. *Cancer Imaging*. 2018;18:14.

Sho T, Suda G, Ogawa K. Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. *JGH Open*. 2019;4:54–60.

Sorafenib [Nexavar® package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2018.

Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein in early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. *Gastroenterology*. 2018;154:1706–1718.

Wang X, Wang Q. Alpha-fetoprotein and hepatocellular carcinoma immunity. *Can J Gastroenterol Hepatol*. 2018;2018:9049252.

Yau T, Park JW, Finn RS. CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced HCC. *Ann Oncol*. 2019;30(Suppl_5):v851–v934.